Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun;23(2):e70083.
doi: 10.1002/msc.70083.

The Effect of Gradual Withdrawal Versus Maintenance of Low-Dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus, a Pilot Double-Blind Randomised Controlled Trial

Supasa Niyompanichakarn  1 , Sumapa Chaiamnuay  1 , Pongthorn Narongroeknawin  1 , Paijit Asavatanabodee  1 , Pornsawan Leosuthamas  1 , Rattapol Pakchotanon  1
Affiliations
Randomized Controlled Trial

The Effect of Gradual Withdrawal Versus Maintenance of Low-Dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus, a Pilot Double-Blind Randomised Controlled Trial

Supasa Niyompanichakarn et al. Musculoskeletal Care. 2025 Jun.

Abstract

Introduction: Abrupt discontinuation of low dose glucocorticoids (GCs) in systemic lupus erythematosus (SLE) patients with clinical quiescent disease increased the risk of flares. This study aimed to evaluate the effect of a gradual GC withdrawal scheme on the flare rate among SLE patients with sustained clinical remission.

Methods: SLE patients who received prednisolone 5 mg/day for at least 4 weeks and had clinical SLE Disease Activity Index-2000 (cSLEDAI-2K) = 0 for a minimum of 6 months were recruited. The participants were randomly assigned in a 1:1 ratio to either the 16-week gradual discontinuation of prednisolone (withdrawal group) or continuation of prednisolone for 24 weeks (maintenance group) with a planned enrolment of 36. The primary outcome was the proportion of patients experiencing a flare, defined with either change of cSLEDAI-2K ≥ 4, SLE-Disease Activity Score ≥ 1.72 or any treatment escalation over 24 weeks.

Results: Twenty patients were assigned to the maintenance group (10 patients), and the withdrawal group (10 patients). The flare rate was higher in the withdrawal group compared with the maintenance group (3 vs. 1 patient; HR 3.57; 95% CI 0.37 to 34.51, p = 0.24). All patients who experienced a flare were serologically active clinically quiescent at screening. Adverse events (AEs) occurred more in the withdrawal group (7 vs. Two patients). The trial was terminated early due to the occurrence of flares and AEs.

Conclusion: Gradual tapering of 5 mg/day of prednisolone showed non-significant higher rate of relapse and AEs in SLE patients with clinical remission.

Clinical trial number: The trial was registered with ClinicalTrials.gov, NCT06234852.

Keywords: drug tapering; glucocorticoid; systemic lupus erythematosus.

PubMed Disclaimer

References

    1. Abe, K., Y. Ishikawa, Y. Kita, et al. 2022. “Association of Low‐Dose Glucocorticoid Use and Infection Occurrence in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study.” Arthritis Research and Therapy 24, no. 1: 179. https://doi.org/10.1186/s13075‐022‐02869‐9.
    1. Al Sawah, S., X. Zhang, B. Zhu, et al. 2015. “Effect of Corticosteroid Use by Dose on the Risk of Developing Organ Damage Over Time in Systemic Lupus Erythematosus‐The Hopkins Lupus Cohort.” Lupus Science & Medicine 2, no. 1: e000066. https://doi.org/10.1136/lupus‐2014‐000066.
    1. Apostolopoulos, D., R. Kandane‐Rathnayake, W. Louthrenoo, et al. 2020. “Factors Associated With Damage Accrual in Patients With Systemic Lupus Erythematosus With No Clinical or Serological Disease Activity: A Multicentre Cohort Study.” Lancet Rheumatology 2, no. 1: e24–e30. https://doi.org/10.1016/S2665‐9913(19)30105‐5.
    1. Burmester, G. R., F. Buttgereit, C. Bernasconi, et al. 2020. “Continuing Versus Tapering Glucocorticoids After Achievement of Low Disease Activity or Remission in Rheumatoid Arthritis (SEMIRA): A Double‐Blind, Multicentre, Randomised Controlled Trial.” Lancet 396, no. 10246: 267–276. https://doi.org/10.1016/s0140‐6736(20)30636‐x.
    1. Fanouriakis, A., M. Kostopoulou, J. Andersen, et al. 2024. “EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update.” J Annals of the Rheumatic Diseases 83, no. 1: 15–29. https://doi.org/10.1136/ard‐2023‐224762.

Publication types

Associated data

Grants and funding